Cytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.

TitleCytomegalovirus-specific immunity and protection against viremia and disease in HIV-infected patients in the era of highly active antiretroviral therapy.
Publication TypeJournal Article
Year of Publication2006
AuthorsWeinberg A, Tierney C, Kendall MA, Bosch RJ, Patterson-Bartlett J, Erice A, Hirsch MS, Polsky B
Corporate AuthorsAIDS Clinical Trials Group 360 Team
JournalJ Infect Dis
Volume193
Issue4
Pagination488-93
Date Published2006 Feb 15
ISSN0022-1899
KeywordsAdult, AIDS-Related Opportunistic Infections, Antiretroviral Therapy, Highly Active, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cytomegalovirus, Cytomegalovirus Infections, Female, HIV Infections, HIV-1, Humans, Interferon-gamma, Male, Multicenter Studies as Topic, Prospective Studies, Viremia
Abstract

To define the immune correlates of protection against cytomegalovirus (CMV) end-organ disease, CMV-specific interferon (IFN)- gamma enzyme-linked immunospot (ELISPOT) and CD8(+) and CD4(+) intracellular IFN- gamma synthesis assays were performed for subjects with CD4(+) cell counts of < or =50 cells/ microL who were enrolled in a prospective observational study of CMV infection in the era of highly active antiretroviral therapy. Of 87 subjects, 46 developed viremia, 14 developed end-organ disease, and 20 died. Positive ELISPOT assay results, but not positive results for CD4(+) or CD8(+) intracellular IFN- gamma synthesis, were associated with delayed development of viremia and CMV end-organ disease or death. CMV viremia did not appear to boost CMV-specific immunity. ELISPOT assays may be used to identify HIV-infected patients who might benefit from anti-CMV prophylactic interventions.

DOI10.1086/499826
Alternate JournalJ. Infect. Dis.
PubMed ID16425127
Grant ListAI--27659 / AI / NIAID NIH HHS / United States
AI-25859 / AI / NIAID NIH HHS / United States
AI-25868 / AI / NIAID NIH HHS / United States
AI-25879 / AI / NIAID NIH HHS / United States
AI-25897 / AI / NIAID NIH HHS / United States
AI-25903-15 / AI / NIAID NIH HHS / United States
AI-25924 / AI / NIAID NIH HHS / United States
AI-27658 / AI / NIAID NIH HHS / United States
AI-27660 / AI / NIAID NIH HHS / United States
AI-27661 / AI / NIAID NIH HHS / United States
AI-27663 / AI / NIAID NIH HHS / United States
AI-27664 / AI / NIAID NIH HHS / United States
AI-27666 / AI / NIAID NIH HHS / United States
AI-27673 / AI / NIAID NIH HHS / United States
AI-27675 / AI / NIAID NIH HHS / United States
AI-32770 / AI / NIAID NIH HHS / United States
AI-32782 / AI / NIAID NIH HHS / United States
AI-32783 / AI / NIAID NIH HHS / United States
AI-34832 / AI / NIAID NIH HHS / United States
AI-34853 / AI / NIAID NIH HHS / United States
AI-38855 / AI / NIAID NIH HHS / United States
AI-38858 / AI / NIAID NIH HHS / United States
AI-41089 / AI / NIAID NIH HHS / United States
AI-46370 / AI / NIAID NIH HHS / United States
AI-46386 / AI / NIAID NIH HHS / United States
AI-50410 / AI / NIAID NIH HHS / United States
HD-33345 / HD / NICHD NIH HHS / United States
RR-00034 / RR / NCRR NIH HHS / United States
RR-00036 / RR / NCRR NIH HHS / United States
RR-00046 / RR / NCRR NIH HHS / United States
RR-00051 / RR / NCRR NIH HHS / United States
RR-00070 / RR / NCRR NIH HHS / United States
RR-05096 / RR / NCRR NIH HHS / United States